Ovalis' Reverse Spin
This article was originally published in Start Up
Most small companies grow for a while and then sell off to a larger acquiror. Ovalis, an intriguing start-up in the PFO space, has reversed the process, beginning as part of Abbott Laboratories' Abbott Vascular Division before being spun off as an independent company.
You may also be interested in...
These are tough times for companies developing PFO closure devices. Various energy-based approaches have hit the rocks, and clinical trial enrollment difficulties have derailed others. Coherex Medical hopes for better results with technology that it describes as safe, user-friendly, and more effective than competing technologies. The company's FlatStent PFO closure system combines a self-expanding stent with tissue growth materials, and a design that provides multiple means to close the PFO and thus boost the chances for long-term success.
For most small device companies, the threat of IP litigation sends chills through senior management. But for PFO start-up, its current battle with AGA Medical can only help, say company officials, by establishing the bona fides of its technology in a crowded space.
Four years ago, lured into a mainstream cardiovascular business by the promise of drug-eluting stents, Abbott set about revamping its medical products business in an effort to create a device business that would rival its pharmaceutical business in financial returns. What was at first a niche strategy, aimed at bringing small, but interesting technologies to interventionalists, has become a more broad-based play that, company officials hope, will place them among the leaders in vascular devices.